Birinapant clinical study initiated by IGM Biosciences
Medivir AB announced that IGM Biosciences initiated a clinical study for birinapant (IGM-9427) in solid cancers, combined with IGM's DR5 agonist antibody IGM-8444. This trial aims to assess safety and tolerability, building on promising preclinical results. Following an exclusive licensing agreement in January 2021, Medivir will receive an additional USD 1.5 million as birinapant enters clinical phase I studies. This marks a significant step in the evaluation of birinapant's potential in oncology, as stated by Interim CEO Magnus Christensen.
- Initiation of clinical study for birinapant in solid cancers with potential for enhanced anti-tumor activity.
- Medivir to receive additional USD 1.5 million as birinapant progresses in clinical trials.
- Strong preclinical results supporting the combination therapy of birinapant and IGM-8444.
- None.
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today announced that IGM Biosciences, Inc. has initiated its clinical study in solid cancers with birinapant (a k a IGM-9427) in combination with IGM's DR5 agonist antibody IGM-8444 (NCT04553692).
The combination of IGM-8444 and birinapant has previously shown to enhance anti-tumor activity preclinically. The purpose of this first clinical trial with the combination will be to explore safety and tolerability.
In January 2021, Medivir entered into an exclusive licensing agreement through which IGM Biosciences received global, exclusive development rights for birinapant. Upon signing the agreement, Medivir received USD 1 million, which will now be followed by an additional USD 1.5 million as birinapant is included by IGM Biosciences in clinical phase I studies.
"We are very happy with this important development step in the clinical evaluation of birinapant's potential within oncology in combination with IGM's antibody IGM-8444" says Magnus Christensen, interim CEO in Medivir.
For further information, please contact:
Magnus Christensen, Interim CEO, CFO, Medivir AB
Phone: +46 (0)8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CET on November 4, 2021.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medivir/r/birinapant-clinical-study-initiated-by-igm-biosciences,c3447452
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/birinapant-clinical-study-initiated-by-igm-biosciences-301416698.html
SOURCE Medivir
FAQ
What is the purpose of the birinapant clinical study initiated by IGM Biosciences?
When was the clinical study for birinapant initiated?
What are the financial implications for Medivir from this clinical study?
What is the significance of the preclinical results for the birinapant study?
What is the stock ticker symbol for Medivir?
